NCT06146127

Brief Summary

Our project is a large-scale characterisation of cHCC-CCA will allow us to determine which subsets harbor actionable gene alterations. We will also aim to improve diagnosis of this tumor type by the use of immunohistochemical biomarkers and the development of deep-learning based models able to help cHCC-CCA diagnosis. This will represent an important step towards precision medicine for the patients with this highly aggressive malignancy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2001

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2001

Completed
22 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2023

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 17, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 24, 2023

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2025

Completed
Last Updated

November 24, 2023

Status Verified

November 1, 2023

Enrollment Period

22 years

First QC Date

November 17, 2023

Last Update Submit

November 17, 2023

Conditions

Liver Cancer

Keywords

livercancerprecision medicine

Outcome Measures

Primary Outcomes (1)

  • Diagnosos

    Tumor subgroups

    3 yrs

Study Arms (3)

Combined hepatocellular cholangiocarcinoma

Other: phenotyping

hepatocellular carcinoma

Other: phenotyping

cholangiocarcinoma

Other: phenotyping

Interventions

phenotypingOTHER

Large scale molecular phenotyping

Combined hepatocellular cholangiocarcinomacholangiocarcinomahepatocellular carcinoma

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adults

You may qualify if:

  • histological diagnosis of combined tumor biological sample available

You may not qualify if:

  • unequivocal histological features

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Julien Calderaro

Créteil, 94010, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

frozen and ffpe samples

MeSH Terms

Conditions

Liver NeoplasmsNeoplasms

Interventions

Immunophenotyping

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Intervention Hierarchy (Ancestors)

Immunologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesImmunologic Techniques

Study Officials

  • Julien Calderaro

    Inserm/APHP

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Julien Calderaro

CONTACT

julien.calderaro@aphp.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Full Professor

Study Record Dates

First Submitted

November 17, 2023

First Posted

November 24, 2023

Study Start

January 15, 2001

Primary Completion

January 15, 2023

Study Completion

January 30, 2025

Last Updated

November 24, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)